Neuropsychiatry and Psychiatric Disorders

OVERVIEW

The Neuropsychiatry and Psychiatric Disorders session will explore the complex relations between neurological and psychiatric conditions. This session aims to bridge the gap between these two fields by exploring the latest research, clinical practices, and therapeutic approaches. Participants will engage with leading experts through interactive discussions, and case studies to better understand the neurobiological foundation of psychiatric disorders and the integrated treatment strategies available.

Understanding the Neurobiological Basis:

This session will explore the intricate relationship between brain function and psychiatric disorders. Presentations will cover recent advancements in neuroimaging, highlighting how abnormalities in brain regions and neurotransmitter systems are linked to psychiatric symptoms. Attendees will present case studies demonstrating how these insights are applied in clinical practice.

Diagnostic Approaches and Challenges:

This segment will focus on the evolving diagnostic frameworks that incorporate both neurological and psychiatric perspectives. Attendees will learn about the challenges in differentiating between primary psychiatric conditions and those secondary to neurological disorders. Interactive case discussions will illustrate how integrated diagnostic approaches enhance patient outcomes.

Future Directions in Treatment:

Attendees will engage with recent developments in treatment options and discuss future directions in neuropsychiatry. Topics will include advancements in pharmacotherapy, novel psychotherapeutic techniques, and emerging neuromodulation treatments. This session will encourage participants to consider how these innovations can be incorporated into practice to improve patient care.

The Neuropsychiatry and Psychiatric Disorders session provides a unique opportunity to gain a comprehensive understanding of the neuropsychiatric aspects of psychiatric disorders. By participating, you'll be equipped with the knowledge to enhance diagnostic accuracy, integrate innovative treatments, and contribute to the advancement of neuropsychiatry.

TOPICS

Key Discussion Areas

Core scientific themes explored across all sessions in this track.

🔬

Interventional Cardiology Advances

Latest techniques in percutaneous coronary intervention, transcatheter structural interventions, and complex bifurcation stenting with outcome data from 2025–2026 trials.

💊

Heart Failure: New Drug Classes

Comprehensive review of SGLT2 inhibitors across HFrEF/HFpEF, mavacamten in HCM, and emerging agents in the pipeline with mechanisms and clinical trial evidence.

🤖

AI in Cardiac Imaging

Clinical validation data for AI tools in echocardiography, cardiac MRI, and CT angiography — including automated ejection fraction, plaque characterisation, and anomaly detection.

🧬

Cardiac Genetics & Cardiomyopathy

CRISPR applications in hereditary cardiomyopathy, genotype-guided risk stratification, and family screening protocols in hypertrophic and dilated cardiomyopathies.

⚡

Arrhythmia & Electrophysiology

Catheter ablation advances in persistent AF, ventricular tachycardia, and SCA prevention strategies including novel antiarrhythmic drug data and wearable monitoring.

🛡️

Preventive Cardiology

Polygenic risk scores in cardiovascular prevention, novel lipid-lowering strategies beyond statins, and population health approaches to primary cardiovascular prevention.

AUDIENCE

Who Should Attend?

This track is designed for clinicians, researchers, and allied health professionals with an interest in neuropsychiatry and psychiatric disorders.

Cardiologists and cardiology trainees
Interventional cardiologists
Cardiac electrophysiologists
Heart failure specialists
Cardiothoracic surgeons
Clinical cardiac physiologists
Internal medicine physicians with cardiovascular interest
Cardiovascular nurses and allied health professionals
Cardiovascular researchers and clinical trialists

Attend Neuropsychiatry and Psychiatric Disorders

Join delegates from 120+ countries for three days of world-class clinical science at the Healthcore Bridge International Medical Conference 2026.

FAQs

Frequently Asked Questions

What is the scope of the Oncology & Haematology track?

The Oncology & Haematology track covers precision oncology, immunotherapy, ADC therapies, haematological malignancies, liquid biopsy and early detection, AI in oncology, and palliative care — across 22 sessions over three conference days. It is the largest scientific track at the 2026 conference.

Will there be separate sessions for haematology and solid tumours?

Yes. The track is structured with dedicated morning sessions for haematological malignancies and afternoon sessions focusing on solid tumour oncology. The final panel each day brings all specialties together for cross-disciplinary discussion.

Are there oncology workshops available?

Yes. Two hands-on workshops complement the oncology track: a molecular tumour board simulation workshop and an AI pathology interpretation masterclass. Both require separate registration due to a 30-delegate capacity limit.

Is this track accredited for oncology-specific CME?

All oncology sessions are accredited for CME under EACCME, AMA PRA Category 1, and the Royal College of Radiologists (for radiation oncologists). Specialty-specific CME credit allocation is detailed in the conference programme and the CME pre-event delegate guide.